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Effect of Metformin on Cardiovascular Risk 
Profile in Patients without Diabetes presenting 
with Acute Myocardial Infarction:
Data	from	the	Glycometabolic	Intervention	as	adjunct	



























(n	 =	 172)	was	 improved	 compared	 to	 placebo	 (n=174);	HbA1c	 (5.83%	 [95	
CI	 5.79–5.87%]	 vs.	 5.89%	 [95%	 CI	 5.85–5.92%]	 (40.2	 mmol/mol	 [95%	 CI	
39.8	–40.6	mmol/mol	 vs.	 40.9	mmol/mol	 [40.4–41.2	mmol/mol,	 P=0.049),	
total	cholesterol	(3.85	mmol/L	[95%	CI	3.73–3.97	mmol/L]	vs.	4.02	mmol/L	
[95%	CI	3.90–4.14	mmol/L],	P=0.045),	LDL-cholesterol	(2.10	mmol/L	[95%	CI	










Metformin and cardiovascular risk profile
INTRODUCTION
After	 ST-segment	 elevation	 myocardial	 infarction	 (STEMI)	 secondary	
prevention	therapies	as	 recommended	by	current	guidelines	such	as	beta-
blockers,	 angiotensin-converting	 enzyme	 inhibitors,	 platelet	 aggregation	
inhibitors	 (acetylsalicylic	 acid	 and	 others),	 and	 lipid	 lowering	 drugs	 all	
have	 been	 proven	 to	 reduce	 mortality	 and	 attenuate	 cardiovascular	 risk	
profile.1	In	addition	to	the	targeted	substrates	by	current	therapies,	such	as	
blood	 pressure,	 neuroendocrine	 activation,	 and	 increased	 thrombogenity,	
glycometabolic	 dysregulation	 is	 strongly	 associated	with	 adverse	 outcome	
after	 STEMI.2	 Impaired	 fasting	 glucose	 and	 insulin	 resistance	 is	 associated	
with	impaired	prognosis,	even	at	levels	of	dysglycemia	not	yet	diagnostic	of	
diabetes	mellitus.3–5	 Dysglycemia	 is	 common	 in	 STEMI	 patients	 –	 as	much	









with	 reduced	 all-cause	 mortality	 compared	 to	 other	 antihyperglycemic	
strategies.9–12	Long-term	metformin	treatment	in	patients	at	risk	for	or	with	
diabetes	 improved	 cardiovascular	 risk	 profile	 mediated	 by	 weight	 loss,	
improved	 insulin	 resistance,	 reduction	of	 the	metabolic	 syndrome,	 and	by	
lowering	total	and	 low-density	 lipoprotein	(LDL)	cholesterol.13–20	Further,	 in	
patients	at	risk	for	diabetes,	but	without	cardiovascular	disease,	metformin	
reduced	diabetes	development	with	30–40%.13–15
	 We	aimed	 to	evaluate	 if	metformin	 treatment,	on	 top	of	 standard	
care,	would	improve	cardiovascular	risk	in	non-diabetic	patients.	We	therefore	
conducted	 this	prespecified	subanalysis	 in	 the	Metabolic	Modulation	With	









double-blind,	 placebo-controlled	 Metabolic	 Modulation	 With	 Metformin	
to	Reduce	Heart	 Failure	After	Acute	Myocardial	 Infarction:	Glycometabolic	
Intervention	 as	 adjunct	 to	 Primary	 Coronary	 Intervention	 in	 ST	 Elevation	
Myocardial	Infarction	(GIPS-III)	trial	have	been	reported	previously.21,22	In	brief,	






















verbal	 informed	 consent	 during	 the	 PCI	 procedure	 and	 the	 first	 dose	was	
administered	immediately	after	arrival	at	the	Coronary	Care	Unit	(CCU).
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	 At	 admission,	 body	weight,	 height,	 blood	 pressure	 and	 heart	 rate	
were	 measured,	 and	 body	 mass	 index	 (BMI)	 was	 calculated.	 Blood	 was	
drawn	during	primary	PCI	and	blood	glucose,	glycated	hemoglobin	(HbA1c),	
insulin,	creatinine,	and	cholesterol	 levels	were	assessed.	A	detailed	history	
including	 cardiovascular	 risk	 profile	 was	 assessed	 during	 hospitalization.	
Patients	arriving	at	the	CCU	between	00:00	AM	and	08:59	PM	were	subjected	
to	 a	 standardized	 oral	 glucose	 tolerance	 test	 (OGTT)	with	 75	 g	 of	 glucose	
(dissolved	 in	200	mL	water)	 the	following	morning.23 In	patients	arriving	at	
the	CCU	between	09:00	PM	and	23:59	PM,	 the	OGTT	was	performed	 the	
second	morning	 after	 admission.	During	 the	OGTT	 in	 the	 CCU	 all	 patients	
had	already	taken	at	least	one	to	maximally	four	tablets	of	study	medication.	
All	 patients	 received	 standard	medication	 according	 to	 current	 guidelines,	
received	 counselling	 on	 diet,	 smoking,	 and	 lifestyle	 and	 were	 offered	 a	




after	 an	overnight	 fast	 of	 at	 least	 eight	 hours.	 In	 order	 to	 assess	whether	
the	 study	medication	actually	affected	underlying	dysglycemia	 rather	 than	
masking	 its	 presence,	 the	 OGTT	 was	 scheduled	 at	 least	 three	 days	 after	
stopping	the	study	medication.
End points and definitions
Primary	outcomes	 in	 this	prespecified	analysis	 from	 the	GIPS-III	 trial	were	
levels	 of,	 and	 change	 in	 HbA1c,	 fasting	 glucose,	 post-challenge	 glucose,	
insulin	 levels,	 cholesterol	 levels,	 body	weight,	 BMI,	 and	 blood	 pressure	 at	
four	months,	adjusting	for	baseline	levels.




(Tosoh	G8,	 Tosoh	 Bioscience	 Inc,	 South	 San	 Francisco,	 USA).	 Insulin	 levels	
were	determined	post-hoc	from	blood	samples	stored	at	-80	degrees	Celsius	






	 An	 independent	 end	 point	 adjudication	 committee,	 blinded	 to	
treatment	allocation,	using	data	on	HbA1c	levels,	OGTT,	and	use	of	medication,	
assessed	 diabetic	 state.	 Diabetes	 was	 defined	 as	 an	 HbA1c	 of	 ≥6.5%	 (48	
mmol/mol),	 and/or	 a	 fasting	 blood	 glucose	 of	 ≥7.0	 mmol/L	 and/or	 a	 2-h	






Continuous	 variables	 are	 reported	 as	means±SD	 or	medians	 [interquartile	
range,	 IQR]	 for	 normally	 and	 non-normally	 distributed	 data,	 respectively.	
Differences	 between	 groups	 were	 tested	 using	 Student’s	 t-test	 or	 ANOVA	
for	normally	distributed	data,	and	Wilcoxon	or	Kruskall-Wallis	tests	for	non-
normally	 distributed	 data.	 Differences	 in	 proportions	were	 assessed	 using	
chi-squared	tests.	ANCOVA	was	used	to	evaluate	differences	 in	continuous	
variables	at	4	months,	adjusting	for	baseline	values,	reported	as	mean	with	





study	 treatment	 as	 fixed	 effects	 (population-level	 estimates)	 and	 allowed	
for	 subject-specific	 variation	 in	 baseline	 levels	 and	 changes	 (a	 so-called	
random	slope,	 random	 intercept	model).	 Linear,	 cubic,	 and	quadratic	time	
transformations	were	considered;	best	fit	for	the	fixed	effects	structure	was	
selected	based	on	AIC	and	BIC	(measures	for	model	fit;	lower	is	better),	while	
the	 best	 random	 effects	 structure	was	 evaluated	 via	 likelihood	 ratio	 tests	
in	 nested	 models.	 The	 interaction	 between	 treatment	 and	 time	 indicates	
whether	 a	 different	 trajectory	 (slope)	 exists	 between	 the	 two	 treatment	
groups.	 All	 reported	 P	 values	 are	 two-sided,	 and	 a	 P-value	 of	 <0.05	 was	
considered	 significant.	 All	 analyses	 were	 performed	 using	 R:	 A	 Language	
and	Environment	 for	 Statistical	Computing,	 version	3.02	 (R	Foundation	 for	
Statistical	Computing,	Vienna,	Austria).
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cardiovascular	 history,	 physical	 diagnostic	 measurements,	 and	 baseline	
markers	reflective	of	renal	function,	glycometabolism,	and	cholesterol	profile.
HbA1c concentration
At	 four	months,	 HbA1c	 levels	 in	 the	metformin	 group	were	 slightly	 lower	
than	in	the	placebo	group,	adjusting	for	baseline	values	(Table 2).	The	mean	
absolute	change	in	HbA1c	concentration	from	baseline	to	four	months	was	
0.06	 (95%	CI	 0.03–0.10%)	 [0.66	mmol/mol	 (95%	CI	 0.33–1.09	mmol/mol)]	
in	 the	metformin	 group	 and	 0.12%	 (95%	 CI	 0.08–0.15%)	 [1.31	mmol/mol	



























Age,	mean	(SD),	years 58·1±11·7 58·1±11·9 58·2±11·6 0·968
Female	sex	–	No.	(%) 87	(25) 40	(23) 47	(27) 0·496
Race	or	ethnic	group	–	No.	(%) 0·567
		Caucasian 335	(97) 168	(98) 167	(96) ?
		Asian 7	(2·0) 3	(1·7) 4	(2·3) ?
		Black 4	(1·2) 1	(0·6) 3	(1·7) ?
Cardiovascular	Risk	Factors	–	No.	(%)
		Hypertension 97	(28) 50	(29) 47	(27) 0·759
		Dyslipidaemia 220	(64) 103	(60) 117	(67) 0·190
		Current	smoking 190	(55) 96	(56) 94	(54) 0·821
		Positive	family	history 118	(34) 55	(32) 63	(36·2) 0·474
Cardiovascular	History
		Stroke 2	(0·6) 1	(0·6) 1	(0·6) 1·000
		Previous	PCI 4	(1) 1	(0·6) 3	(1·7) 0·623
Physical	diagnostics	at	hospital	admission
		Body	weight,	mean	(SD),	kg 83·5±14.0 83·6	±13·9 83·3±14·1 0·847
		Body-mass	Index,	mean	(SD),	kg/m2 26·7±3·7 26·5±3·5 26·9±3·9 0·401
		Systolic	blood	pressure,	mean	(SD),	mmHg 134±23 134±22 133±24 0·797
		Diastolic	blood	pressure,	mean	(SD),	mmHg 84±14 84±14 84±15 0·733
Laboratory	values	at	admission
		Haemoglobin	(IQR),	mmol/L 8·9±0·8 8·9±0·8 8·9±0·8 0·673
		Creatinine	(IQR),	µmol/L 72	(62–82) 72	(62–84) 73	(63–81) 0·673
		Estimated	GFR	(IQR),	(mL/min/173m2) 93±21 93±23	 93±19 0·947
		Glucose,	median	(IQR),	mmol/L 8·1	(7·0–9·4) 8·1	(7·0–9·2) 8·1	(7·0–9·6) 0·627
		HbA1c,	median	(IQR),	% 5·8	(5·6–6·0) 5·7	(5·6–6·0) 5·8	(5·6–6·0) 0·849
		Insulin,	median	(IQR),	mmol/L 16·9	(9·8–29·2) 18·5	(10·8–30·1) 15·9	(9·3–27·8) 0·169
		HbA1c,	median	(IQR),	mmol/mol 40	(38–42) 39	(38–42) 40	(38–42) 0.849
		Total	cholesterol	(IQR),	mmol/L 5·3	(4·8–6·0) 5·3	(4·7–6·1) 5·3	(4·8–6·0) 0·938
		LDL	cholesterol	(IQR),	mmol/L 3·8	(3·2–4·4) 3·7	(3·1–4·5) 3·8	(3·3–4·4) 0·740
		HDL	cholesterol	(IQR),	mmol/L 1·1	(0·9–1·3) 1·1	(0·9–1·3) 1·1	(0·9–1·3) 0·821




mmol/L	 vs.	 5.6±0.7	mmol/L,	 P=0.76)	 and	 the	 120	minutes	 post	 challenge	
glucose	levels	(7.7±2.2	mmol/L	vs.	7.8±2.2	mmol/L,	P=0.83)	(Figure 3B).
Insulin levels
Twenty-four	hours	after	PCI,	 the	non-fasting	 insulin	 level	 in	 the	metformin	
group	was	 34.5mU/L	 (95%	CI	 29.3–39.6	mU/L)	 and	 33.2	mU/L	 (28.4–38.1	
mU/L)	in	the	placebo	group;	(P=0.274).	The	mean	absolute	change	in	insulin	
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Figure 1. Change in Markers of Glycometabolism and Cardiovascular Risk Profile.	Absolute	
changes	in	(95%	CI)	in	the	metformin	and	placebo	groups	in	HbA1c	concentration	(A),	insulin	
levels	 (B),	 body	 weight	 (C),	 total	 cholesterol	 (D),	 LDL	 cholesterol	 (E),	 and	 HDL	 cholesterol	




(63%)	 and	 in	 123	 patients	 (71%)	 in	 the	 placebo	 group	 (P=0.40)	 after	 four	
months.
Body Weight and Body-Mass Index




(Figure 1C).	 As	 a	 consequence	 the	 BMI	 at	 four	months	 was	 lower	 in	 the	




in	 the	metformin	 group	 had	 quit	 smoking,	 vs.	 63	 patients	 in	 the	 placebo	
group	(P=0.39).
Total, LDL and HDL Cholesterol
The	 adjusted	 total	 cholesterol	 levels	 and	 LDL-cholesterol	 levels	 in	 the	
metformin	group	were	lower	than	the	placebo	group	after	four	months	(Table 
Figure 2. Change in HbA1c over time.	Trajectories	of	change	in	HbA1c	over	time	(95%	CI)	were	
analysed	using	 linear	mixed-effects	model,	 showing	different	 trajectories	between	 the	 two	
treatment	groups	(P=0.031).	HbA1c	denotes	glycated	hemoglobin.
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2).	The	mean	reduction	from	baseline	to	four	months	in	total	cholesterol	in	
the	metformin	group	was	1.58	mmol/L	 (95%	CI	1.45–1.70	mmol/L)	 and	 in	
the	placebo	group	1.40	mmol/L	(95%	CI	1.29–1.52	mmol/L;	P=0.045;	Figure 
1D),	whereas	the	mean	reduction	in	LDL	cholesterol	was	1.74	mmol/L	(95%	





in	 the	 placebo	 group	 (P=0.153;	 Figure 1F).	 At	 baseline	 only	 two	 patients	
in	 the	metformin	group	and	 three	patient	 in	 the	placebo	group	had	a	LDL	
cholesterol	level	of	<	1.9	mmol/L,	which	is	the	targeted	level	for	cholesterol	



































A) During Hospitalisation B) At 4 months 
Fasting 120 min Post Challenge Fasting 120 min Post Challenge 
P=0·03 
















The	main	observation	of	 this	prespecified	analysis	 from	the	GIPS-III	 trial	 is	
that	metformin	treatment	for	four	months	on	top	of	standard	care	leads	to	an	
improved	cardiovascular	risk	profile	compared	to	placebo	in	STEMI	patients	
without	 diabetes.	 HbA1c	 levels,	 weight	 gain,	 total	 cholesterol,	 and	 LDL	
cholesterol	levels	were	all	lower	in	patients	receiving	metformin.	A	reduction	
in	 the	 incidence	 of	 new	 onset	 diabetes	 was	 not	 observed.	 Furthermore,	
systolic	and	diastolic	blood	pressure,	insulin	levels,	and	HDL	cholesterol	levels	





	 Our	 result	 concerning	 HbA1c	 levels	 are	 comparable	 with	 results	
from	 the	 recent	 Carotid	 Atherosclerosis:	MEtformin	 for	 insulin	 ResistAnce	
(CAMERA)	 study,	 that	 demonstrated	 that	 18	 months	 of	 treatment	 with	
metformin	 in	 patients	with	 coronary	 artery	 disease	without	 diabetes	 also	
resulted	in	a	reduction	of	HbA1c	levels.18	The	Diabetes	Prevention	Program	
(DPP)	demonstrated	that	3	years	of	treatment	with	metformin	850	mg	twice	
daily	significantly	 lowered	HbA1c	 in	comparison	to	placebo,	however	 their	
population	consisted	solely	of	patients	with	prediabetes	and	therefore	a	more	
substantial	reduction	compared	to	our	study	population	is	to	be	expected.13 
The	 use	 of	 markers	 of	 HbA1c	 as	 a	 diagnostic	 marker	 is	 not	 unequivocal.	
However,	 the	 incremental	 prognostic	 value	 of	 HbA1c	 on	 top	 of	 standard	
risk	 factors	has	been	established.25	 Therefore,	 it	 is	 generally	accepted	 that	
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lowering	HbA1c	likely	is	associated	with	improved	prognosis.
	 During	 hospitalization,	 1	 to	 maximally	 4	 dosages	 of	 metformin	
treatment	 already	 resulted	 in	 a	 lower	 post-challenge	 blood	 glucose	
concentrations	 compared	 to	 placebo.	 Since	 we	 did	 not	 measure	 fasting	
insulin	levels	24h	after	PCI,	this	effect	could	be	due	to	directly	lowering	insulin	
resistance,	but	also	due	to	other	glucose	lowering	effects	of	metformin,	such	
as	 reduction	 of	 hepatic	 gluconeogenesis	may	 be	 of	 effect.	 Hyperglycemia	
is	 often	 present	 during	 and	 the	 days	 following	myocardial	 infarction,	 and	
is	 associated	 with	 impaired	 myocardial	 reperfusion,	 larger	 myocardial	
infarct	 size,	 and	 impaired	outcome.3	 Therefore,	many	 studies	using	 insulin	














		Body	weight,	mean	(95%	CI),	kg 83·8	(83·0–84·7) 85·2	(84·4–86·1) 0·024
		Body-mass	Index,	mean	(95%	CI),	kg/








		HbA1c,	mean	(95%	CI),	% 5·83	(5·79–5·87) 5·89	(5·85–5·92) 0·049
		HbA1c,	mean	(95%	CI),	mmol/mol 40.2	(39.8–40.6) 40.9	(40.4–41.2) 0.049










Values	 were	 calculated	 using	 ANCOVA,	 adjusted	 for	 baseline	 variables.	 Abbreviations:	




adverse	 effect.	 Our	 analysis	 suggests	 that	 metformin	 can	 lower	 glucose	
levels	during	STEMI,	without	 the	adverse	effects	of	 insulin-based	 lowering	
strategies.	Whether	administration	of	metformin	prior	to	reperfusion,	with	


















total	 cholesterol	 levels	on	 top	of	 initiation	of	 statin	 therapy.	 The	BIGPRO1	
study	showed	that	metformin	treatment	for	1	year	resulted	 in	a	reduction	








disease,	 but	 at	 hospital	 discharge	 99.5%	of	 patients	 in	 our	 study	 received	













All	 end	points	were	 adjudicated	by	 an	 independent	 end	point	 committee.	





sufficient	 to	 address	 cardiovascular	 risk	 profile.	 The	 study	medication	was	
only	administered	for	4	months,	which	in	terms	of	secondary	prevention	is	
short.
	 Altogether,	 we	 observed	 that	 metformin	 treatment	 in	 patients	
without	 diabetes	 presenting	with	 STEMI,	 resulted	 in	 prevention	of	 gain	 in	
body	weight,	improved	levels	of	HbA1	and	improved	levels	of	LDL	and	total	
cholesterol.	 Estimating	 the	 total	 effect	 size	on	 cardiovascular	 risk	 of	 these	





prognosis	 in	 patients	 with	 STEMI	 are	 warranted.	 Currently,	 the	 Glucose	
Lowering	 in	 Non-diabetic	 hyperglycemia	 Trial	 (GLINT,	 ISRCTN34875079),	
is	 an	ongoing	double-blind	 randomized	 controlled	 trial	 set	 to	 include	over	
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